DK2907522T3 - Fremgangsmåde til øgning af knoglehårdhed og stivhed og reduktion af frakturer - Google Patents
Fremgangsmåde til øgning af knoglehårdhed og stivhed og reduktion af frakturer Download PDFInfo
- Publication number
- DK2907522T3 DK2907522T3 DK15152726.4T DK15152726T DK2907522T3 DK 2907522 T3 DK2907522 T3 DK 2907522T3 DK 15152726 T DK15152726 T DK 15152726T DK 2907522 T3 DK2907522 T3 DK 2907522T3
- Authority
- DK
- Denmark
- Prior art keywords
- bone
- pth
- use according
- cortical
- fracture
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title description 288
- 230000001965 increasing effect Effects 0.000 title description 82
- 230000009467 reduction Effects 0.000 title description 28
- 238000000034 method Methods 0.000 title description 23
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 171
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 171
- 239000000199 parathyroid hormone Substances 0.000 claims description 171
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims description 60
- 206010041569 spinal fracture Diseases 0.000 claims description 32
- 239000011575 calcium Substances 0.000 claims description 22
- 229910052791 calcium Inorganic materials 0.000 claims description 22
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 21
- 208000001132 Osteoporosis Diseases 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 16
- 241000282412 Homo Species 0.000 claims description 13
- 239000003755 preservative agent Substances 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- 229930003316 Vitamin D Natural products 0.000 claims description 7
- 239000006172 buffering agent Substances 0.000 claims description 7
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-methyl-PhOH Natural products CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 7
- 235000019166 vitamin D Nutrition 0.000 claims description 7
- 239000011710 vitamin D Substances 0.000 claims description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 7
- 229940046008 vitamin d Drugs 0.000 claims description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000003717 m-cresyl group Chemical group [H]C1=C([H])C(O*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
- 229960001950 benzethonium chloride Drugs 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 229960003742 phenol Drugs 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 claims description 2
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 description 135
- 230000001054 cortical effect Effects 0.000 description 83
- 206010017076 Fracture Diseases 0.000 description 62
- 238000011282 treatment Methods 0.000 description 57
- 208000010392 Bone Fractures Diseases 0.000 description 45
- 230000000694 effects Effects 0.000 description 38
- 229910052500 inorganic mineral Inorganic materials 0.000 description 32
- 239000011707 mineral Substances 0.000 description 32
- 210000000689 upper leg Anatomy 0.000 description 28
- 241000283973 Oryctolagus cuniculus Species 0.000 description 26
- 210000002758 humerus Anatomy 0.000 description 25
- 230000008901 benefit Effects 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 22
- 230000011164 ossification Effects 0.000 description 20
- 239000000463 material Substances 0.000 description 18
- 241000282693 Cercopithecidae Species 0.000 description 17
- 241000288906 Primates Species 0.000 description 16
- 210000002436 femur neck Anatomy 0.000 description 16
- 210000001624 hip Anatomy 0.000 description 15
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000037118 bone strength Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000008416 bone turnover Effects 0.000 description 11
- 238000007634 remodeling Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000001195 anabolic effect Effects 0.000 description 10
- 230000033558 biomineral tissue development Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 210000004705 lumbosacral region Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 208000014674 injury Diseases 0.000 description 8
- 210000002303 tibia Anatomy 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- 230000007306 turnover Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 6
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 6
- 241000282567 Macaca fascicularis Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 210000003275 diaphysis Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000002485 urinary effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 102100036893 Parathyroid hormone Human genes 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 206010065687 Bone loss Diseases 0.000 description 4
- 238000000305 Fourier transform infrared microscopy Methods 0.000 description 4
- 210000003423 ankle Anatomy 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 229910003460 diamond Inorganic materials 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000001564 haversian system Anatomy 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000004197 pelvis Anatomy 0.000 description 4
- 210000000614 rib Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 238000003957 acoustic microscopy Methods 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000001089 mineralizing effect Effects 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 230000002250 progressing effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002320 radius Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000006670 Multiple fractures Diseases 0.000 description 2
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 2
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 2
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 2
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010049264 Teriparatide Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000123 anti-resoprtive effect Effects 0.000 description 2
- 238000011444 antiresorptive therapy Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000013001 point bending Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960005460 teriparatide Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N Alizarin Natural products C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001135732 Bos taurus Parathyroid hormone Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 101710164303 N-succinylamino acid racemase Proteins 0.000 description 1
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 1
- 101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- -1 for example Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010045624 glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 102000058004 human PTH Human genes 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001930 leg bone Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010198 maturation time Effects 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 101710125387 o-succinylbenzoate synthase Proteins 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000682 scanning probe acoustic microscopy Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229940086546 synarel Drugs 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Materials For Medical Uses (AREA)
Claims (13)
1. Human PTH(l-34) til anvendelse til forebyggelse eller reduktion af hyppigheden af vertebral og ikke-vertebral fraktur hos et menneske med eller med risiko for udvikling af osteoporose, hvor: PTH(l-34) indgives ved subkutan injektion ved en dosis på 20 pg/dag, hvor mennesket også modtager effektive doser af calcium og D-vitamin; og PTH(l-34) formuleres med en buffer og en excipiens, med et buffermiddel, der er i stand til at opretholde opløsningen ved et pH-område fra 3 til 7.
2. Human PTH(l-34) til anvendelse ifølge krav 1, hvor buffermidlet er i stand til at opretholde opløsningen ved et pH-område fra 3 til 6.
3. Human PTH(l-34) til anvendelse ifølge krav 2, hvor buffermidlet er acetat, tartrat eller citrat.
4. Human PTH(l-34) til anvendelse ifølge et hvilket som helst af de foregående krav, hvor koncentrationen af buffer er i området fra 2 mM til 500 mM.
5. Human PTH(l-34) til anvendelse ifølge krav 4, hvor koncentrationen af buffer er i området fra 2 mM til 100 mM.
6. Human PTH(l-34) til anvendelse ifølge et hvilket som helst foregående krav, hvor PTH(l-34) formuleres i en stabiliseret opløsning omfattende et stabiliseringsmiddel, et buffermiddel og et konserveringsmiddel.
7. Human PTH(l-34) til anvendelse ifølge krav 6, hvor konserveringsmidlet er valgt fra kresoler, benzylalkohol, phenol, benzalkoniumchlorid, benzethoniumchlorid, chlorbutanol, phenylethylalkohol, methylparaben, propylparaben, thimerosal og phenylmerkuri-nitrat og -acetat.
8. Human PTH(l-34) til anvendelse ifølge krav 7, hvor konserveringsmidlet er m-kresol eller benzylalkohol.
9. Human PTH(l-34) til anvendelse ifølge krav 8, hvor konserveringsmidlet er m-kresol.
10. Human PTH(l-34) til anvendelse ifølge et hvilket som helst af de foregående krav, hvor mængden af konserveringsmiddel varierer fra 0,1 til 2 vægtprocent af den samlede opløsning.
11. Human PTH(l-34) til anvendelse ifølge krav 10, hvor mængden af konserveringsmiddel varierer fra 0,3 til 1,0 vægtprocent af den samlede opløsning.
12. Human PTH(l-34) til anvendelse ifølge et hvilket som helst af de foregående krav, hvor mennesket er en kvinde.
13. Human PTH(l-34) til anvendelse ifølge krav 12, hvor kvinden er en postmenopausal kvinde.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9715198P | 1998-08-19 | 1998-08-19 | |
| US9974698P | 1998-09-10 | 1998-09-10 | |
| EP10180447.4A EP2266598B1 (en) | 1998-08-19 | 1999-08-19 | Method of increasing bone toughness and stiffness and reducing fractures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2907522T1 DK2907522T1 (da) | 2015-10-19 |
| DK2907522T3 true DK2907522T3 (da) | 2017-10-23 |
Family
ID=26792729
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15152726.4T DK2907522T3 (da) | 1998-08-19 | 1999-08-19 | Fremgangsmåde til øgning af knoglehårdhed og stivhed og reduktion af frakturer |
| DK10180447.4T DK2266598T3 (da) | 1998-08-19 | 1999-08-19 | Fremgangsmåde til at øge knoglehårdhed og -stivhed og at reducere brud |
| DK06027055.0T DK1769804T3 (da) | 1998-08-19 | 1999-08-19 | hPTH(1-34) til anvendelse ved forebyggelse eller reduktion af forekomsten eller voldsomheden af vertebral og/eller ikke-vertebral fraktur hos en mand |
| DK99942350T DK1059933T3 (da) | 1998-08-19 | 1999-08-19 | Anvendelse af parathyroideahormon bestående af aminosyresekvens 1-34 af humant parathyroideahormon til reduktion af risikoen for både hvirvel- og ikke-hvirvel knoglefraktur |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10180447.4T DK2266598T3 (da) | 1998-08-19 | 1999-08-19 | Fremgangsmåde til at øge knoglehårdhed og -stivhed og at reducere brud |
| DK06027055.0T DK1769804T3 (da) | 1998-08-19 | 1999-08-19 | hPTH(1-34) til anvendelse ved forebyggelse eller reduktion af forekomsten eller voldsomheden af vertebral og/eller ikke-vertebral fraktur hos en mand |
| DK99942350T DK1059933T3 (da) | 1998-08-19 | 1999-08-19 | Anvendelse af parathyroideahormon bestående af aminosyresekvens 1-34 af humant parathyroideahormon til reduktion af risikoen for både hvirvel- og ikke-hvirvel knoglefraktur |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US6977077B1 (da) |
| EP (3) | EP2266598B1 (da) |
| JP (5) | JP2002523375A (da) |
| KR (1) | KR100454207B1 (da) |
| CN (1) | CN1205997C (da) |
| AR (1) | AR033639A1 (da) |
| AT (1) | ATE231000T1 (da) |
| AU (1) | AU746277B2 (da) |
| BR (1) | BR9909445A (da) |
| CA (1) | CA2325371C (da) |
| CO (1) | CO5130020A1 (da) |
| CY (2) | CY1113343T1 (da) |
| CZ (1) | CZ301017B6 (da) |
| DE (2) | DE15152726T1 (da) |
| DK (4) | DK2907522T3 (da) |
| DZ (1) | DZ2873A1 (da) |
| EA (1) | EA003362B1 (da) |
| ES (4) | ES2393200T3 (da) |
| HK (3) | HK1030545A1 (da) |
| HR (1) | HRP20000755A2 (da) |
| HU (2) | HU230697B1 (da) |
| ID (1) | ID29039A (da) |
| IL (2) | IL138829A0 (da) |
| MY (1) | MY129227A (da) |
| NO (2) | NO323984B1 (da) |
| NZ (1) | NZ507056A (da) |
| PE (1) | PE20001089A1 (da) |
| PL (1) | PL201688B1 (da) |
| PT (4) | PT1769804E (da) |
| TR (1) | TR200003455T2 (da) |
| TW (1) | TW576747B (da) |
| UA (1) | UA72205C2 (da) |
| WO (1) | WO2000010596A1 (da) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770623B1 (en) * | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| AR033639A1 (es) | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
| US20040033950A1 (en) * | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| EP1222465A1 (en) * | 1999-09-20 | 2002-07-17 | Eli Lilly And Company | Method for monitoring treatment with a parathyroid hormone |
| US7247609B2 (en) | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
| EP1531855A4 (en) | 2002-01-10 | 2009-07-22 | Osteotrophin Llc | TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA |
| US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| MXPA06003064A (es) * | 2003-09-19 | 2006-05-31 | Pfizer Prod Inc | Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y hormona paratiroide. |
| US20060127320A1 (en) * | 2004-05-10 | 2006-06-15 | Nastech Pharmaceutical Company Inc. | Method of delivering parathyroid hormone to a human |
| RU2006143544A (ru) * | 2004-05-10 | 2008-06-20 | Нэстек Фармасьютикал Кампани Инк. (Us) | Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона |
| US20060052305A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | Method of treating osteoporosis using intranasal parathyroid hormone |
| US20060189533A1 (en) * | 2004-05-10 | 2006-08-24 | Nastech Pharmaceutical Company Inc. | Stable pharmaceutical dosage forms of teriparatide |
| BRPI0509788A (pt) | 2004-05-13 | 2007-10-23 | Alza Corp | aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides |
| US7648965B2 (en) | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
| US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
| EP1879608A4 (en) * | 2005-05-11 | 2009-11-11 | Unigene Lab Inc | METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION |
| US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
| JP2009515535A (ja) * | 2005-11-10 | 2009-04-16 | ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー | クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法 |
| US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
| US20080119408A1 (en) * | 2006-07-07 | 2008-05-22 | Nastech Pharmaceutical Company Inc. | Pth formulations for intranasal delivery |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| WO2008125655A1 (en) | 2007-04-13 | 2008-10-23 | Kuros Biosurgery Ag | Polymeric tissue sealant |
| US20110137243A1 (en) * | 2007-09-06 | 2011-06-09 | Abbott Cardiovascular Systems Inc. | Coating On A Balloon Device |
| US9457056B2 (en) * | 2007-12-04 | 2016-10-04 | Ben-Gurion University Of The Negev Research And Development Authority | Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis |
| EP2227263A2 (en) | 2007-12-28 | 2010-09-15 | Kuros Biosurgery AG | Pdgf fusion proteins incorporated into fibrin foams |
| KR20170089018A (ko) | 2009-09-09 | 2017-08-02 | 아사히 가세이 파마 가부시키가이샤 | 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제 |
| EP2509996A1 (en) | 2009-12-07 | 2012-10-17 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US9295663B2 (en) | 2010-07-14 | 2016-03-29 | Abbott Cardiovascular Systems Inc. | Drug coated balloon with in-situ formed drug containing microspheres |
| WO2012111852A1 (ja) * | 2011-02-17 | 2012-08-23 | 帝人ファーマ株式会社 | 椎体骨折治療剤及びその評価方法 |
| WO2012123028A1 (en) | 2011-03-16 | 2012-09-20 | Kuros Biosurgery Ag | Pharmaceutical formulation for use in spinal fusion |
| KR20150116467A (ko) | 2011-06-07 | 2015-10-15 | 아사히 가세이 파마 가부시키가이샤 | 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법 |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| CN108601833B (zh) * | 2016-02-01 | 2022-11-15 | 伊莱利利公司 | 甲状旁腺激素-抗rankl抗体融合化合物 |
| US20190381341A1 (en) * | 2017-02-01 | 2019-12-19 | The Johns Hopkins University | Parathyroid hormone and regeneration of degenerative discs disease |
| JP6577683B2 (ja) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| CN111447943A (zh) | 2018-10-29 | 2020-07-24 | 旭化成制药株式会社 | 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法 |
| EP4010360A1 (en) | 2019-08-09 | 2022-06-15 | Flagship Pioneering Innovations VI, LLC | Modulators of parathyroid hormone receptor (pthr1) |
| GB2590692A (en) * | 2019-12-24 | 2021-07-07 | Corthotec Ltd | Composition for improved bone fracture healing |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| DE3935738A1 (de) | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
| US5208041A (en) | 1991-05-23 | 1993-05-04 | Allelix Biopharmaceuticals Inc. | Essentially pure human parathyroid hormone |
| US5556940A (en) | 1994-06-20 | 1996-09-17 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
| JPH0873376A (ja) * | 1994-09-07 | 1996-03-19 | Asahi Chem Ind Co Ltd | 骨粗鬆症治療薬 |
| EP0800405A4 (en) * | 1994-12-19 | 1998-11-11 | Beth Israel Hospital | CONTINUOUS ADMINISTRATION OF LOW DOSES OF HORMONE PARATHYRO DIENNE OR ITS AGONIST |
| US5747456A (en) * | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
| ATE238043T1 (de) * | 1994-12-22 | 2003-05-15 | Astrazeneca Ab | Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation |
| JPH08310965A (ja) * | 1995-05-16 | 1996-11-26 | Chugai Pharmaceut Co Ltd | 骨癒合促進剤 |
| HU226866B1 (en) * | 1997-09-09 | 2009-12-28 | Hoffmann La Roche | Fracture healing using pthrp analogs |
| ZA9811127B (en) | 1997-12-09 | 2000-07-11 | Lilly Co Eli | Stabilized teriparatide solutions. |
| US20040033950A1 (en) | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| AR033639A1 (es) * | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
| US6907597B1 (en) | 2000-10-13 | 2005-06-14 | Ati International Srl | Method and apparatus for constructing an executable program in memory |
| US6967759B2 (en) | 2001-12-31 | 2005-11-22 | Texas Instruments Incorporated | Pulse width modulation sequence generation |
| JP5796714B2 (ja) | 2012-01-13 | 2015-10-21 | 株式会社リコー | 定着装置及び画像形成装置 |
| EP2949301B1 (en) | 2014-05-27 | 2018-04-18 | The Procter and Gamble Company | Absorbent core with curved and straight absorbent material areas |
-
1999
- 1999-08-18 AR ARP990104133A patent/AR033639A1/es unknown
- 1999-08-18 DZ DZ990173A patent/DZ2873A1/xx active
- 1999-08-19 BR BR9909445-2A patent/BR9909445A/pt not_active Application Discontinuation
- 1999-08-19 EA EA200001015A patent/EA003362B1/ru not_active IP Right Cessation
- 1999-08-19 CN CNB998083534A patent/CN1205997C/zh not_active Expired - Lifetime
- 1999-08-19 KR KR10-2001-7002092A patent/KR100454207B1/ko not_active IP Right Cessation
- 1999-08-19 DK DK15152726.4T patent/DK2907522T3/da active
- 1999-08-19 PT PT06027055T patent/PT1769804E/pt unknown
- 1999-08-19 DE DE15152726.4T patent/DE15152726T1/de active Pending
- 1999-08-19 EP EP10180447.4A patent/EP2266598B1/en not_active Expired - Lifetime
- 1999-08-19 CO CO99052525A patent/CO5130020A1/es unknown
- 1999-08-19 US US09/647,278 patent/US6977077B1/en not_active Expired - Lifetime
- 1999-08-19 NZ NZ507056A patent/NZ507056A/en not_active IP Right Cessation
- 1999-08-19 CZ CZ20004134A patent/CZ301017B6/cs not_active IP Right Cessation
- 1999-08-19 JP JP2000565916A patent/JP2002523375A/ja active Pending
- 1999-08-19 WO PCT/US1999/018961 patent/WO2000010596A1/en active IP Right Grant
- 1999-08-19 ES ES06027055T patent/ES2393200T3/es not_active Expired - Lifetime
- 1999-08-19 AT AT99942350T patent/ATE231000T1/de not_active IP Right Cessation
- 1999-08-19 CA CA002325371A patent/CA2325371C/en not_active Expired - Lifetime
- 1999-08-19 UA UA2000095457A patent/UA72205C2/uk unknown
- 1999-08-19 AU AU55750/99A patent/AU746277B2/en not_active Expired
- 1999-08-19 PT PT15152726T patent/PT2907522T/pt unknown
- 1999-08-19 PL PL343595A patent/PL201688B1/pl not_active IP Right Cessation
- 1999-08-19 EP EP99942350A patent/EP1059933B1/en not_active Revoked
- 1999-08-19 DK DK10180447.4T patent/DK2266598T3/da active
- 1999-08-19 DK DK06027055.0T patent/DK1769804T3/da active
- 1999-08-19 PT PT101804474T patent/PT2266598T/pt unknown
- 1999-08-19 PT PT99942350T patent/PT1059933E/pt unknown
- 1999-08-19 HU HU0101594A patent/HU230697B1/hu unknown
- 1999-08-19 DK DK99942350T patent/DK1059933T3/da active
- 1999-08-19 IL IL13882999A patent/IL138829A0/xx unknown
- 1999-08-19 ES ES10180447.4T patent/ES2621653T3/es not_active Expired - Lifetime
- 1999-08-19 EP EP15152726.4A patent/EP2907522B1/en not_active Revoked
- 1999-08-19 HU HUP1200430 patent/HU1200430D0/hu not_active Application Discontinuation
- 1999-08-19 TR TR2000/03455T patent/TR200003455T2/xx unknown
- 1999-08-19 ES ES15152726.4T patent/ES2549551T3/es not_active Expired - Lifetime
- 1999-08-19 ES ES99942350T patent/ES2190244T3/es not_active Expired - Lifetime
- 1999-08-19 PE PE1999000839A patent/PE20001089A1/es not_active Application Discontinuation
- 1999-08-19 MY MYPI99003553A patent/MY129227A/en unknown
- 1999-08-19 ID IDW20010612A patent/ID29039A/id unknown
- 1999-08-19 DE DE69904918T patent/DE69904918T2/de not_active Expired - Lifetime
- 1999-10-26 TW TW088114185A patent/TW576747B/zh not_active IP Right Cessation
-
2000
- 2000-10-03 IL IL138829A patent/IL138829A/en unknown
- 2000-11-06 HR HR20000755A patent/HRP20000755A2/hr not_active Application Discontinuation
- 2000-11-24 NO NO20005947A patent/NO323984B1/no not_active IP Right Cessation
-
2001
- 2001-02-14 HK HK01101056A patent/HK1030545A1/xx unknown
-
2005
- 2005-04-05 US US11/098,894 patent/US7163684B2/en not_active Expired - Lifetime
-
2007
- 2007-06-11 NO NO20072983A patent/NO20072983L/no not_active Application Discontinuation
- 2007-10-04 HK HK07110798.6A patent/HK1102496A1/xx unknown
-
2010
- 2010-10-29 JP JP2010244314A patent/JP2011021035A/ja not_active Withdrawn
-
2012
- 2012-11-14 CY CY20121101096T patent/CY1113343T1/el unknown
-
2014
- 2014-03-25 JP JP2014061763A patent/JP6177718B2/ja not_active Expired - Lifetime
- 2014-10-03 JP JP2014204577A patent/JP2015028065A/ja not_active Withdrawn
-
2016
- 2016-01-18 HK HK16100519.4A patent/HK1212602A1/zh not_active IP Right Cessation
-
2017
- 2017-06-26 JP JP2017124301A patent/JP2017190332A/ja not_active Withdrawn
- 2017-10-13 CY CY20171101077T patent/CY1119552T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2907522T3 (da) | Fremgangsmåde til øgning af knoglehårdhed og stivhed og reduktion af frakturer | |
| US7351414B2 (en) | Method of reducing the risk of bone fracture | |
| Turner et al. | The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys | |
| EP1136076A1 (en) | Method of increasing bone toughness and stiffness and reducing fractures | |
| EP1769804A2 (en) | Method of increasing bone toughness and stiffness and reducing fractures | |
| MXPA00009982A (en) | Method of increasing bone toughness and stiffness and reducing fractures |